346 related articles for article (PubMed ID: 16187085)
1. Vaccination of melanoma patients using dendritic cells loaded with an allogeneic tumor cell lysate.
Salcedo M; Bercovici N; Taylor R; Vereecken P; Massicard S; Duriau D; Vernel-Pauillac F; Boyer A; Baron-Bodo V; Mallard E; Bartholeyns J; Goxe B; Latour N; Leroy S; Prigent D; Martiat P; Sales F; Laporte M; Bruyns C; Romet-Lemonne JL; Abastado JP; Lehmann F; Velu T
Cancer Immunol Immunother; 2006 Jul; 55(7):819-29. PubMed ID: 16187085
[TBL] [Abstract][Full Text] [Related]
2. Dendritic cells loaded with killed allogeneic melanoma cells can induce objective clinical responses and MART-1 specific CD8+ T-cell immunity.
Palucka AK; Ueno H; Connolly J; Kerneis-Norvell F; Blanck JP; Johnston DA; Fay J; Banchereau J
J Immunother; 2006; 29(5):545-57. PubMed ID: 16971810
[TBL] [Abstract][Full Text] [Related]
3. Clinical response after intradermal immature dendritic cell vaccination in metastatic melanoma is associated with immune response to particulate antigen.
Smithers M; O'Connell K; MacFadyen S; Chambers M; Greenwood K; Boyce A; Abdul-Jabbar I; Barker K; Grimmett K; Walpole E; Thomas R
Cancer Immunol Immunother; 2003 Jan; 52(1):41-52. PubMed ID: 12536239
[TBL] [Abstract][Full Text] [Related]
4. Dendritic cell immunizations alone or combined with low doses of interleukin-2 induce specific immune responses in melanoma patients.
Escobar A; López M; Serrano A; Ramirez M; Pérez C; Aguirre A; González R; Alfaro J; Larrondo M; Fodor M; Ferrada C; Salazar-Onfray F
Clin Exp Immunol; 2005 Dec; 142(3):555-68. PubMed ID: 16297169
[TBL] [Abstract][Full Text] [Related]
5. Phase II trial of dendritic cells loaded with antigens from self-renewing, proliferating autologous tumor cells as patient-specific antitumor vaccines in patients with metastatic melanoma: final report.
Dillman RO; Selvan SR; Schiltz PM; McClay EF; Barth NM; DePriest C; de Leon C; Mayorga C; Cornforth AN; Allen K
Cancer Biother Radiopharm; 2009 Jun; 24(3):311-9. PubMed ID: 19538053
[TBL] [Abstract][Full Text] [Related]
6. Vaccination of Japanese patients with advanced melanoma with peptide, tumor lysate or both peptide and tumor lysate-pulsed mature, monocyte-derived dendritic cells.
Nakai N; Asai J; Ueda E; Takenaka H; Katoh N; Kishimoto S
J Dermatol; 2006 Jul; 33(7):462-72. PubMed ID: 16848818
[TBL] [Abstract][Full Text] [Related]
7. Phase I/II study of treatment with dendritic cell vaccines in patients with disseminated melanoma.
Hersey P; Menzies SW; Halliday GM; Nguyen T; Farrelly ML; DeSilva C; Lett M
Cancer Immunol Immunother; 2004 Feb; 53(2):125-34. PubMed ID: 14600790
[TBL] [Abstract][Full Text] [Related]
8. Active immunization of metastatic melanoma patients with interleukin-2-transduced allogeneic melanoma cells: evaluation of efficacy and tolerability.
Belli F; Arienti F; Sulé-Suso J; Clemente C; Mascheroni L; Cattelan A; Santantonio C; Gallino GF; Melani C; Rao S; Colombo MP; Maio M; Cascinelli N; Parmiani G
Cancer Immunol Immunother; 1997 Jun; 44(4):197-203. PubMed ID: 9222277
[TBL] [Abstract][Full Text] [Related]
9. Route of administration modulates the induction of dendritic cell vaccine-induced antigen-specific T cells in advanced melanoma patients.
Lesterhuis WJ; de Vries IJ; Schreibelt G; Lambeck AJ; Aarntzen EH; Jacobs JF; Scharenborg NM; van de Rakt MW; de Boer AJ; Croockewit S; van Rossum MM; Mus R; Oyen WJ; Boerman OC; Lucas S; Adema GJ; Punt CJ; Figdor CG
Clin Cancer Res; 2011 Sep; 17(17):5725-35. PubMed ID: 21771874
[TBL] [Abstract][Full Text] [Related]
10. Vaccination with autologous dendritic cells pulsed with multiple tumor antigens for treatment of patients with malignant melanoma: results from a phase I/II trial.
Trepiakas R; Berntsen A; Hadrup SR; Bjørn J; Geertsen PF; Straten PT; Andersen MH; Pedersen AE; Soleimani A; Lorentzen T; Johansen JS; Svane IM
Cytotherapy; 2010 Oct; 12(6):721-34. PubMed ID: 20429791
[TBL] [Abstract][Full Text] [Related]
11. [Vaccine therapy of malignant melanoma. II. Serological evaluation of the immune responses to the injection using allogeneic melanoma cell vaccine].
Takeyama H; Watanabe T; Livingston PO
Gan To Kagaku Ryoho; 1983 Jul; 10(7):1624-33. PubMed ID: 6870307
[TBL] [Abstract][Full Text] [Related]
12. Clinical evaluation of liposomal tumor antigen vaccines in patients with stage-III melanoma.
Phillips NC; Loutfi A; A-Kareem AM; Shibata HR; Baines MG
Cancer Detect Prev; 1990; 14(4):491-6. PubMed ID: 2224912
[TBL] [Abstract][Full Text] [Related]
13. Humoral immune response to intralymphatic immunotherapy for disseminated melanoma: correlation with clinical response.
Ahn SS; Irie RF; Weisenburger TH; Jones PC; Juillard G; Roe DJ; Morton DL
Surgery; 1982 Aug; 92(2):362-7. PubMed ID: 7101129
[TBL] [Abstract][Full Text] [Related]
14. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells.
Nestle FO; Alijagic S; Gilliet M; Sun Y; Grabbe S; Dummer R; Burg G; Schadendorf D
Nat Med; 1998 Mar; 4(3):328-32. PubMed ID: 9500607
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of T-Cell Responses Against Shared Melanoma Associated Antigens and Predicted Neoantigens in Cutaneous Melanoma Patients Treated With the CSF-470 Allogeneic Cell Vaccine Plus BCG and GM-CSF.
Podaza E; Carri I; Aris M; von Euw E; Bravo AI; Blanco P; Ortiz Wilczyñski JM; Koile D; Yankilevich P; Nielsen M; Mordoh J; Barrio MM
Front Immunol; 2020; 11():1147. PubMed ID: 32582212
[TBL] [Abstract][Full Text] [Related]
16. Dendritic cell-based vaccination in metastatic melanoma patients: phase II clinical trial.
Oshita C; Takikawa M; Kume A; Miyata H; Ashizawa T; Iizuka A; Kiyohara Y; Yoshikawa S; Tanosaki R; Yamazaki N; Yamamoto A; Takesako K; Yamaguchi K; Akiyama Y
Oncol Rep; 2012 Oct; 28(4):1131-8. PubMed ID: 22895835
[TBL] [Abstract][Full Text] [Related]
17. Vaccination with autologous dendritic cells loaded with autologous tumor lysate or homogenate combined with immunomodulating radiotherapy and/or preleukapheresis IFN-α in patients with metastatic melanoma: a randomised "proof-of-principle" phase II study.
de Rosa F; Ridolfi L; Ridolfi R; Gentili G; Valmorri L; Nanni O; Petrini M; Fiammenghi L; Granato AM; Ancarani V; Pancisi E; Soldati V; Cassan S; Riccobon A; Parisi E; Romeo A; Turci L; Guidoboni M
J Transl Med; 2014 Jul; 12():209. PubMed ID: 25053129
[TBL] [Abstract][Full Text] [Related]
18. Phase 2 trial of vaccination with tyrosinase peptides and granulocyte-macrophage colony-stimulating factor in patients with metastatic melanoma.
Scheibenbogen C; Schmittel A; Keilholz U; Allgäuer T; Hofmann U; Max R; Thiel E; Schadendorf D
J Immunother; 2000; 23(2):275-81. PubMed ID: 10746554
[TBL] [Abstract][Full Text] [Related]
19. Complementary vaccination protocol with dendritic cells pulsed with autologous tumour lysate in patients with resected stage III or IV melanoma: protocol for a phase II randomised trial (ACDC Adjuvant Trial).
Ridolfi L; de Rosa F; Fiammenghi L; Petrini M; Granato AM; Ancarani V; Pancisi E; Soldati V; Cassan S; Bulgarelli J; Riccobon A; Gentili G; Nanni O; Framarini M; Tauceri F; Guidoboni M
BMJ Open; 2018 Aug; 8(8):e021701. PubMed ID: 30082356
[TBL] [Abstract][Full Text] [Related]
20. Randomized phase II trial of lymphodepletion plus adoptive cell transfer of tumor-infiltrating lymphocytes, with or without dendritic cell vaccination, in patients with metastatic melanoma.
Saberian C; Amaria RN; Najjar AM; Radvanyi LG; Haymaker CL; Forget MA; Bassett RL; Faria SC; Glitza IC; Alvarez E; Parshottam S; Prieto V; Lizée G; Wong MK; McQuade JL; Diab A; Yee C; Tawbi HA; Patel S; Shpall EJ; Davies MA; Hwu P; Bernatchez C
J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 34021033
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]